Liminal Biosciences Inc (DELISTED) (LMNL:DL)
8.50
0.00 (0.00%)
USD |
NASDAQ |
Sep 26, 16:00
Liminal Biosciences Cash from Operations (TTM): -27.11M for June 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2023 | -27.11M |
| March 31, 2023 | -26.54M |
| December 31, 2022 | -24.46M |
| September 30, 2022 | -30.07M |
| June 30, 2022 | -66.12M |
| March 31, 2022 | -68.46M |
| December 31, 2021 | -79.45M |
| September 30, 2021 | -88.67M |
| June 30, 2021 | -57.76M |
| March 31, 2021 | -55.79M |
| December 31, 2020 | -56.66M |
| September 30, 2020 | -63.41M |
| June 30, 2020 | -63.08M |
| March 31, 2020 | -79.13M |
| December 31, 2019 | -74.89M |
| September 30, 2019 | -68.43M |
| June 30, 2019 | -63.67M |
| March 31, 2019 | -51.09M |
| December 31, 2018 | -63.63M |
| September 30, 2018 | -62.37M |
| June 30, 2018 | -83.05M |
| March 31, 2018 | -93.57M |
| December 31, 2017 | -94.58M |
| September 30, 2017 | -100.62M |
| June 30, 2017 | -87.69M |
| Date | Value |
|---|---|
| March 31, 2017 | -86.48M |
| December 31, 2016 | -73.77M |
| September 30, 2016 | -59.15M |
| June 30, 2016 | -50.61M |
| March 31, 2016 | -44.89M |
| December 31, 2015 | -35.76M |
| September 30, 2015 | -33.06M |
| June 30, 2015 | -30.57M |
| March 31, 2015 | -24.12M |
| December 31, 2014 | -23.51M |
| September 30, 2014 | -23.31M |
| June 30, 2014 | -23.47M |
| March 31, 2014 | -17.75M |
| December 31, 2013 | -16.51M |
| September 30, 2013 | -8.295M |
| June 30, 2013 | -2.755M |
| March 31, 2013 | -3.504M |
| December 31, 2012 | -2.134M |
| September 30, 2012 | -3.332M |
| June 30, 2012 | -4.822M |
| March 31, 2012 | -6.770M |
| December 31, 2011 | -7.445M |
| September 30, 2011 | -9.152M |
| June 30, 2011 | -10.10M |
| March 31, 2011 | -8.602M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-88.67M
Minimum
Sep 2021
-24.46M
Maximum
Dec 2022
-58.45M
Average
-63.41M
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
| Acasti Pharma Inc | -13.57M |
| Aurinia Pharmaceuticals Inc | -33.46M |
| Edesa Biotech Inc | -6.252M |
| Lexaria Bioscience Corp | -5.209M |
| Xenon Pharmaceuticals Inc | -145.33M |